The Zhitong Finance App learned that on August 7, the CDE official website announced that the marketing application for a new indication of Sanofi (SNY.US) nicevirumab injection was accepted, and the registration classification was 3.1. Based on public information and clinical trial progress, the Insight database speculates that the declared indications are to prevent lower respiratory infections caused by the following infant respiratory syncytial virus (RSV): newborns and infants who are about to enter or are born during the second RSV infection season.

<palign=center> </palign=center> Screenshot source: CDE official website

Nicevirumab is a single-dose long-acting antibody vaccine jointly developed by Sanofi and AstraZeneca. With just one dose, it provides rapid protection through antibodies to help prevent lower respiratory diseases caused by RSV without activating the immune system.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.